Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2007 1
2008 1
2010 1
2011 1
2013 2
2014 6
2015 1
2016 2
2017 1
2018 4
2019 4
2020 1
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Identification of novel azaindazole CCR1 antagonist clinical candidates.
Harcken C, Kuzmich D, Cook B, Mao C, Disalvo D, Razavi H, Swinamer A, Liu P, Zhang Q, Kukulka A, Skow D, Patel M, Patel M, Fletcher K, Sherry T, Joseph D, Smith D, Canfield M, Souza D, Bogdanffy M, Berg K, Brown M. Harcken C, et al. Bioorg Med Chem Lett. 2019 Feb 1;29(3):441-448. doi: 10.1016/j.bmcl.2018.12.024. Epub 2018 Dec 13. Bioorg Med Chem Lett. 2019. PMID: 30595446
BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C. Chalmers SA, et al. Among authors: harcken c. Clin Immunol. 2018 Dec;197:205-218. doi: 10.1016/j.clim.2018.10.008. Epub 2018 Oct 16. Clin Immunol. 2018. PMID: 30339790 Free PMC article.
Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357.
Harcken C, Csengery J, Turner M, Wu L, Liang S, Sibley R, Brunette S, Labadia M, Hoyt K, Wayne A, Wieckowski T, Davis G, Panzenbeck M, Souza D, Kugler S, Terenzio D, Collin D, Smith D, Fryer RM, Tseng YC, Hehn JP, Fletcher K, Hughes RO. Harcken C, et al. ACS Med Chem Lett. 2021 Jan 5;12(1):143-154. doi: 10.1021/acsmedchemlett.0c00575. eCollection 2021 Jan 14. ACS Med Chem Lett. 2021. PMID: 33488976 Free PMC article.
RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients.
Venken K, Jacques P, Mortier C, Labadia ME, Decruy T, Coudenys J, Hoyt K, Wayne AL, Hughes R, Turner M, Van Gassen S, Martens L, Smith D, Harcken C, Wahle J, Wang CT, Verheugen E, Schryvers N, Varkas G, Cypers H, Wittoek R, Piette Y, Gyselbrecht L, Van Calenbergh S, Van den Bosch F, Saeys Y, Nabozny G, Elewaut D. Venken K, et al. Among authors: harcken c. Nat Commun. 2019 Jan 2;10(1):9. doi: 10.1038/s41467-018-07911-6. Nat Commun. 2019. PMID: 30602780 Free PMC article.
Discovery and optimization of pyrazole amides as antagonists of CCR1.
Harcken C, Sarko C, Mao C, Lord J, Raudenbush B, Razavi H, Liu P, Swinamer A, Disalvo D, Lee T, Lin S, Kukulka A, Grbic H, Patel M, Patel M, Fletcher K, Joseph D, White D, Amodeo L, Berg K, Brown M, Thomson DS. Harcken C, et al. Bioorg Med Chem Lett. 2019 Feb 1;29(3):435-440. doi: 10.1016/j.bmcl.2018.11.015. Epub 2018 Nov 9. Bioorg Med Chem Lett. 2019. PMID: 30455146
Late-stage optimization of a tercyclic class of S1P3-sparing, S1P1 receptor agonists.
Horan JC, Kuzmich D, Liu P, DiSalvo D, Lord J, Mao C, Hopkins TD, Yu H, Harcken C, Betageri R, Hill-Drzewi M, Patenaude L, Patel M, Fletcher K, Terenzzio D, Linehan B, Xia H, Patel M, Studwell D, Miller C, Hickey E, Levin JI, Smith D, Kemper RA, Modis LK, Bannen LC, Chan DS, Mac MB, Ng S, Wang Y, Xu W, Lemieux RM. Horan JC, et al. Among authors: harcken c. Bioorg Med Chem Lett. 2016 Jan 15;26(2):466-471. doi: 10.1016/j.bmcl.2015.11.090. Epub 2015 Nov 26. Bioorg Med Chem Lett. 2016. PMID: 26687487
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.
Litzenburger T, Steffgen J, Benediktus E, Müller F, Schultz A, Klein E, Ramanujam M, Harcken C, Gupta A, Wu J, Wiebe S, Li X, Flack M, Padula SJ, Visvanathan S, Hünnemeyer A, Hui J. Litzenburger T, et al. Among authors: harcken c. Br J Clin Pharmacol. 2021 Apr;87(4):1824-1838. doi: 10.1111/bcp.14571. Epub 2020 Nov 20. Br J Clin Pharmacol. 2021. PMID: 32986868 Free PMC article. Clinical Trial.
An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients.
Bassolas-Molina H, Raymond E, Labadia M, Wahle J, Ferrer-Picón E, Panzenbeck M, Zheng J, Harcken C, Hughes R, Turner M, Smith D, Calderón-Gómez E, Esteller M, Carrasco A, Esteve M, Dotti I, Corraliza AM, Masamunt MC, Arajol C, Guardiola J, Ricart E, Nabozny G, Salas A. Bassolas-Molina H, et al. Among authors: harcken c. Front Immunol. 2018 Oct 22;9:2307. doi: 10.3389/fimmu.2018.02307. eCollection 2018. Front Immunol. 2018. PMID: 30405600 Free PMC article.
23 results